44 / 88
44
Scientific Programme /
Tuesday, 20 June 2017
WFSBP 2017
TUE
024
The normalization of brain F-18-FDG hypometab-
olism following electroconvulsive therapy in a woman
with treatment-resistant depression: Case report
Se-Hoon Shim, Republic of Korea
J.-S. Kim
025
Effects of Neurexan
®
on emotional brain response
Luisa Fensky, Germany
A. Kühnel, V. Teckentrup, M. Schultz, Y. Fan, M. Walter
026
Neurexan
®
influences stress-induced activity of the
anterior cingulate cortex and associated brain regions
Anne Kuehnel, Germany
Y. Fan, L. Fensky, V. Teckentrup, M. Schultz, M. Walter
P-09
POSTER TOUR
13:00–14:30
Congress Hall A 1
Bipolar disorder
Chair:
Andrew A. Nierenberg, USA
001
Probable postpartum hypomania and depression in
a South African cohort
Leigh van den Heuvel, South Africa
J. Pingo, B. Vythylingum, S. Seedat
002
Garcinia mangostana linn (mangosteen) pericarp
as an add-on treatment for bipolar depression
Melanie Ashton, Australia
M. Berk, C. Ng, M. Hopwood, O. Dean
003
Neurocognitive profile, personality, temperament
and creativity in euthymic patients with Bipolar Disor-
der (BP) and major depressive disorder
Nam-Woo Kim, Republic of Korea
E.-Y. Kim, S.-H. Kim, H.-J. Lee, Y.-M. Ahn
004
Obvious impairment of attention and processing
speed in patients with schizoaffective disorder
Chih-Ken Chen, Taiwan
L.-J. Wang
005
Bipolar Disorder (BP) and pregnancy desire
Isaac Gonzalez Gonzalez, Spain
A. Hernández Dorta
006
Eating disorders in Bipolar Disorder I (BP)
Nuria Corominas, Spain
D. Alberca, S. Alberca
007
Modeling mitochondrial damage in human neuro-
nal cells by various concentrations of two mitochondrial
complex inhibitors
Nofar Shemesh, Israel
O. Damri, T. Bar-Yosef, G. Las, G. Agam
009
Cognitive Subgroups in First Episode Bipolar I
Disorder: Relation to Clinical and Brain Volumetric
Variables
Trisha Chakrabarty, Canada
I. Torres, L. Yatham
011
High consumption of caffeine and maniac episode
Alejandro Hernández Dorta, Spain
I. Gonzalez Gonzalez
012
Effects of cognitive remediation for bipolar disor-
ders on neurocognition and psychosocial functioning:
results of a randomized controlled study
Clemence Isaac, France
M.-C. Castillo, F. Durand, O. Bolloré, S. Braha-Zeitoun,
V. Moulier, D. Januel
013
The association between school achievement and
subsequent development of Bipolar Disorder (BP)
Steffie Damgaard Pedersen, Denmark
L. Petersen, O. Mors, S. Dinesen Østergaard
014
International multisite survey of Internet use by
patients with Bipolar Disorder (BD): Use of online sup-
port groups
Rita Bauer, Germany
T. Glenn, J. Conell, M. Bauer
015
Drugs used to treat Bipolar Disorder (BP) act via
microRNAs to regulate expression of genes involved in
neurogenesis and neurite outgrowth
Srisaiyini Kidnapillai, Australia
B. Wade, C. Bortolasci, B. Panizzutti, B. Spolding,
T. Connor, A. Sanigorski, T. Crowley, S. Jamain, L. Gray,
M. Leboyer, M. Berk, K. Walder
016
Can a gene expression signature be used to iden-
tify drugs that may be repurposed for Bipolar Disorder
(BP)?
Chiara Bortolasci, Australia
S. Kidnapillai, B. Panizzutti, B. Spolding, T. Connor,
A. Sanigorski, T. Crowley, S. Jamain, L. Gray, M. Leboyer,
M. Berk, K. Walder
017
Volumetric integrity of the pituitary gland in
Bipolar Disorder (BP)
Gian Mario Mandolini, Italy
G. Delvecchio, C. Perlini, M. Barillari, M. Ruggeri,
A. C. Altamura, M. Bellani, P. Brambilla
018
BDNF and COMT polymorphism with lithium
response in bipolar disorder: a pharmacogenetic asso-
ciation study
Pradip Paul, India
R. K. Nadella, S. Sen, V. Kapur, D. S. Vartak, R. Nayak,
D. Raveendranathan, N. S. Moily, L. N. Kota, B. Viswanath,
M. Purushottam, Y. C. Janardhan Reddy, S. Jain